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to enhance the uptake of HP to brain via intranasal (i.n.) delivery. SLNs were prepared by a modiﬁed
emulsiﬁcation–diffusion technique and evaluated for particle size, zeta potential, drug entrapment
efﬁciency, in vitro drug release, and stability. All parameters were found to be in an acceptable range.
In vitro drug release was found to be 94.1674.78% after 24 h and was ﬁtted to the Higuchi model with a
very high correlation coefﬁcient (R2¼0.9941). Pharmacokinetics studies were performed on albino Wistar
rats and the concentration of HP in brain and blood was measured by high performance liquid
chromatography. The brain/blood ratio at 0.5 h for HP-SLNs i.n., HP sol. i.n. and HP sol. i.v. was 1.61,
0.17 and 0.031, respectively, indicating direct nose-to-brain transport, bypassing the blood–brain
barrier. The maximum concentration (Cmax) in brain achieved from i.n. administration of HP-SLNs
(329.17720.89 ng/mL, Tmax 2 h) was signiﬁcantly higher than that achieved after i.v. (76.9577.62 ng/mL,
Tmax 1 h), and i.n. (90.1376.28 ng/mL, Tmax 2 h) administration of HP sol. The highest drug-targeting
efﬁciency (2362.43%) and direct transport percentage (95.77%) was found with HP-SLNs as compared to
the other formulations. Higher DTE (%) and DTP (%) suggest that HP-SLNs have better brain targeting
efﬁciency as compared to other formulations.
& 2014 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. Open access under CC BY-NC-ND license. l Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by
5
Pharmaceutics, ITS Pharmacy College, Muradnagar, Ghaziabad 201206, Uttar Pradesh, India. Tel.: þ91 9761131206;
com (Mohd Yasir).
itute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
ND license. 
Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation 4551. Introduction
Nanotechnology has several applications in the ‘real world’1. It
encompasses the production and application of physical, chemical
and biological systems at submicron level as well as the integra-
tion of resulting nanostructures into larger systems2,3.
Over the past two decades, there has been a marked improve-
ment in our understanding of the underlying etiology and treat-
ment of central nervous system (CNS) disorders4. However, many
of the drugs used to treat these disorders lack an effective means
for crossing the blood–brain barrier (BBB)5. The BBB presents a
great obstacle to the transport of exogenous substances into the
brain. Thus, various approaches like BBB disruption (osmotic and
biochemical), drug manipulation (prodrug, lipophilic analogs,
chemical drug delivery, carrier mediated drug delivery, and
receptor/vector-mediated drug delivery) and alteration in the route
of administration, including intracerebroventricular, intrathecal,
and olfactory pathways (intranasal route) are used for the targeting
of drugs to the brain6.
In the present scenario, the intranasal route to bypass the BBB
is explored, as this route provides a novel, practical, simple and
non-invasive approach to bypass the blood brain barrier and
reduces the systemic exposure and thus systemic adverse effects7.
Drug after intranasal administration reaches the olfactory epithe-
lium region of the nasal mucosa that acts as a gateway for
substances entering the CNS due to the neural connection between
the nasal mucosa and the brain8.
Haloperidol (HP) is a dopamine inverse agonist of the typical
antipsychotic class of medications that chemically belongs to
butyrophenone group. It occurs as a white crystalline powder and
is chemically known as 4-(4-chlorophenyl)-1-[4-(4-ﬂuorophenyl)-
4-oxobutyl]-4-piperidinol] with molecular weight of 375.86 g/mol
and log P¼3.36. Its mechanism of action is mediated by blockade
of D2 dopamine receptors in brain9. It is used to treat certain
psychiatric conditions including schizophrenia, manic states,
medication-induced psychosis and neurological disorders with
hyperkinesias10. It is also used to treat extreme behavior problems
in children and to ease the symptoms of Tourette's syndrome11.
After oral drug delivery, the drug undergoes ﬁrst-pass metabolism
followed by systemic distribution, resulting in only a small portion
being able to reach the brain through the blood12,13. The plasma–
protein binding of HP is about 90%, thereby further affecting
oral bioavailability12. Speciﬁc clinical complications associated
with a high systemic concentration include respiratory disturbance
(bronchospasm and increased depth of respiration), dermatological
reactions (maculopapular and acneiform skin reactions), nausea,
vomiting and musculoskeletal disorder14–16.
Therefore, a drug delivery system is required which not only
provides rapid and targeted delivery to brain but also reduces
systemic exposure. Attempts have been made to bypass the BBB,
and it has been demonstrated in earlier studies that the intranasal
route bypasses the BBB17.
Solid lipid nanoparticles (SLNs) were introduced in 1991 as
submicron colloidal carriers (50–1000 nm). They are used for both
hydrophilic and lipophilic drug(s) which are trapped in biocompa-
tible lipid core made up of a lipid or combination of lipids like
compritol 888 ATO, precirol ATO 5, glyceryl monostearate,
palmitic acid, stearic acid, as well as others, and stabilized by
surfactant present at the outer shell18. SLNs have the several
advantages including targeted drug delivery and controlled release
delivery, and increase bioavailability so as to reduce the dose and
adverse effects19. SLNs with polymeric nanoparticles offer lowertoxicity. They have good tolerability and biodegradability, lack of
acute and chronic toxicity of the carrier, and scalability20,21.
SLNs offer an improvement to traditional nose-to-brain drug
delivery since they are able to protect the encapsulated drug from
biological and/or chemical degradation and may also increase
nasal retention time due to an occlusive effect, good application
properties, and adhesion of the SLNs to mucous membranes17.
The objectives of the current study were to evaluate HP-SLNs
prepared by the modiﬁed solvent emulsiﬁcation–diffusion
technique, study the stability of the optimized formulation, and
the pharmacokinetics of optimized HP-SLNs after intranasal
administration.2. Materials and methods
2.1. Materials
Haloperidol (HP) was received as a gift from Vamsi Labs Ltd.
(Solapur, Maharashtra, India). Compritol ATO 888, glyceryl
monostearate (GMS) and Precirol ATO 5 were obtained as a gift
from Gattefosse (Witten, Germany). Stearic acid, palmitic acid,
acetonitrile (ACN), triethylamine (TEA), o-phosphoric acid (o-PA)
and Tween 80 along with all the other chemicals were purchased
from Sigma-Aldrich (New Delhi, India). ACN, TEA, o-PA were
high-performance liquid chromatography (HPLC)-grade while all
other solvents and chemicals used were of analytical grade. Water
was distilled and ﬁltered before use through a 0.22 mm membrane
ﬁlter.
2.2. Methods
2.2.1. Excipients selection
Solubility of drug in melted lipid is one of the most important
factors that determine the encapsulation efﬁciency of a drug in
lipid. However, equilibrium solubility studies cannot be carried out
in this case. Hence, we used a modiﬁed method to identify the
solid lipid having best solubilization potential for drug22. GMS,
compritol ATO 888, precirol ATO 5, stearic acid and palmitic acid
were screened for their potential to solubilize HP.
HP (20 mg) was placed in a screw-cap vial. The solid lipids
were separately heated above their melting point. These lipid melts
were gradually added in portions to the vial containing HP with
continuous stirring using a vortex mixer and maintaining the same
temperature (above the melting point of lipid). The end point was
the formation of a clear, pale yellow solution of molten lipid. The
amount of molten lipid required to solubilize the HP was noted
visually. The experiment was performed in triplicate. The compat-
ibility between the lipids and drug was identiﬁed by Fourier
transform-infrared spectrophotometer (Alpha model Bruker ATR-
FTIR spectrophotometer). IR spectra of drug, lipid and a physical
mixture of drug and lipid (1:1) were scanned from 4000 cm1 to
400 cm1 and recorded.
2.2.2. Preparation of SLNs
In a preliminary laboratory study, various factors like ratio of drug
to lipid (1:2), surfactant concentration (Tween 80, 1.5% w/v),
ratio of chloroform to ethanol (1:1, 2.5% v/v) (as the solvent for
drug and lipid), homogenization time (30 min), stirring time (2 h),
stirring speed (2500 rpm), and sonication time (5 min) were
ﬁxed and their effect on particle size and entrapment efﬁciency
was determined. Factors like ratio of drug to lipid, surfactant
Table 1 Composition of various batches of HP-SLNs.
Formulation Variable
Drug (mg) Lipid (mg) Surfactant (% w/v) Stirring speed (rpm) Stirring time (h)
OH1 50 100 1.5 3000 2
OH2 43.75 87.5 1.5 3000 2
OH3 43.75 87.5 1.625 3000 2
OH4 50 100 1.625 3000 2
OPH 50 100 1.625 3000 2.5
Table 2 Solubility of drug in various lipids.
Lipid name Melting point
of lipid (1C)
Amount of lipid
requireda
Glyceryl monostearate 59 47.6670.95
Compritol 888 ATO 70 49.5170.83
Precirol ATO 5 56 55.3472.24
Stearic acid 69 82.8972.10
Palmitic acid 63 142.3772.06
aData are expressed as mean7SD, n¼3.
Mohd Yasir, Udai Vir Singh Sara456concentration, stirring speed and stirring time were further
optimized in this study. All of the experiments were performed
in triplicate and the averages were considered as the response.
Table 1 shows the composition of various batches.
Drug-loaded SLNs were prepared by the modiﬁed solvent
emulsiﬁcation–diffusion technique19,23–25. Accurately weighed
lipid (87.5–100 mg) was dissolved in a 2.5 mL mixture of ethanol
and chloroform (1:1) as the internal oil phase. Drug (43.75–50 mg,
ratio of drug to lipid 1:2) was dispersed in the above solution. This
organic phase was then added drop by drop into a homogenizer
tube containing 22.5 mL of an aqueous solution of Tween 80
(1.5–1.625% w/v) as the external aqueous phase and homogenized
for 30 min at 3000 rpm (Remi Instruments Pvt. Ltd., India) to form
a primary emulsion (o/w). The above primary emulsion was
poured into 75 mL of ice-cold water (2–3 1C) containing surfactant
(1.5–1.625% w/v) and stirred to extract the organic solvent into the
continuous phase and for proper solidiﬁcation of SLNs. The
stirring was continued for 2–2.5 h at 3000 rpm to disperse the
SLNs. The SLN dispersion was sonicated for 5 min (1 cycle,
100% amplitude, Bandelin sonoplus, Germany) to produce SLN
dispersions of uniform size. The dispersion was then centrifuged at
18,000 rpm for 20 min (Remi Instruments Pvt., Ltd., India) to
separate the solid lipid material containing the drug and washed
with deionized water several time to ensure the complete removal
of organic solvent. This was then redispersed in 1.5–1.625% (w/v)
of an aqueous surfactant mixture of Tween 80 and sonicated for
5 min to obtain the SLNs. The SLN dispersions were lyophilized
in the presence of 5% (w/v) mannitol as a cryoprotectant.
2.2.3. Particle size, zeta potential and morphology study
Average particle size, polydispersity index (PDI) and zeta potential
were measured by photon correlation spectroscopy (PCS; Zetasi-
zer, HAS 3000; Malvern Instruments, Malvern, UK). The analysis
was performed at 25 1C with an angle of detection 90126.
Surface morphology of optimized SLNs (OPH) was determined
by using transmission electron microscopy (TEM, Philips CM 10,
Holland). To perform the TEM observation, SLN dispersions
(approx. 10 mL) were dropped on a 300 mesh copper grid coated
with carbon ﬁlm and allowed to sit for 10 min until air-dried. After
complete drying the sample was stained with 2% w/v phospho-
tungstic acid solution with several replications and dried at room
temperature. Digital micrograph and Soft Imaging Viewer soft-
ware were used to perform the image capture and analysis.
2.2.4. Drug loading and drug entrapment efﬁciency
determination
A ﬁxed quantity of HP-SLN dispersions (10 mL) was fractionated
(Remi Instruments, Pvt. Ltd., India) at 18,000 rpm for 20 min at20 1C23. The supernatant fraction was analyzed spectrophotometrically
at λmax of 247.5 nm (Shimadzu 1800, Japan) for determination of
unencapsulated drug27,28. The drug loading (%) and drug entrapment
efﬁciency (%) were calculated by using the following equations21,23:
Drug loadingð%Þ ¼ W t–W sð Þ= W t–W s þWLð Þ  100 ð1Þ
Drug entrapment efficiency ð%Þ ¼ W t–W sð Þ=W t  100 ð2Þ
where Wt is the total weight of drug used, Ws is the weight of drug
in the supernatant after centrifugation and WL is the weight of the
lipid used in preparing the SLNs.
2.2.5. X-ray diffractometric analysis
X-ray powder diffraction patterns of drug, lipid and optimized HP-
SLNs were measured by X-ray diffractometer (PANanalytical,
X’Pert Pro model, Germany) equipped with an X-ray generator.
Analysis was performed on the samples using Cu Kα radiation
(45 kV, 40 mA) and scanned from 51 to 901 (2θ). The scanning
rate is 21/min using an automatic divergence slit assembly and a
proportional detector. Samples were scanned at 25 1C 29.
2.2.6. Differential scanning calorimetry
The thermograms of drug, lipid and optimized HP-SLNs were
recorded with a DSC (Pyris 6 DSC Perkin Elmer, CT, USA) under
an inert atmosphere which was maintained by purging with
nitrogen. Sample (5 mg) was loaded into an aluminum pan and
sealed tightly. An empty aluminum pan was used as a reference.
Samples were heated at a scanning rate of 10 1C/min over a
temperature range between 40–230 1C and the thermograms were
recorded30.
2.2.7. In vitro drug release and release kinetics study
Drug release from HP-SLNs was determined using a dialysis bag
diffusion technique using a dialysis membrane (Himedia, mole-
cular weight cut off 12,000–14,000 D)31. An accurately weighed
amount of HP-SLN containing the drug equivalent to 10 mg was
Figure 1 IR spectra of HP (a), GMS (b) and physical mixture of HP and GMS (c).
Table 3 Observed responses of various batches.
Formulation code Response
Particle size (nm)a PDI Zeta potential (mV) Entrapment efﬁciency (%)a Drug loading (%)a
OH1 146.3473.59 0.479 13.68 69.6570.89 25.8272.45
OH2 156.7773.95 0.453 14.56 68.3572.67 23.4770.57
OH3 150.2575.76 0.437 16.12 70.4372.56 23.9770.95
OH4 140.4972.97 0.429 15.98 70.6571.78 26.0171.23
OPH 115.1072.78 0.409 16.70 71.5671.56 26.3570.56
aData are expressed as mean7SD, n¼3.
Figure 2 TEM image of optimized HP-SLNs.
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suspended in a beaker containing 100 mL of phosphate buffer pH
7.4 and stirred at a constant speed at 3770.5 1C. Aliquots were
withdrawn at predetermined time intervals up to 24 h from receiver
compartment (beaker) and replaced with an equal volume of fresh
medium to maintain a ‘sink’ condition. The samples were analyzed
spectrophotometrically at λmax of 247.5 nm (Shimadzu 1800,
Japan). In vitro release data was ﬁtted to zero order, ﬁrst order
and Higuchi release models32,33. The percent cumulative amountof drug release versus time was plotted for zero kinetics, log
percent drug remaining versus time was plotted for ﬁrst order
kinetics and percent cumulative amount of drug release versus
square root of time was plotted for the Higuchi release model and
the correlation coefﬁcient was determined for each model. Initial
equations for various models are given below:
Zero order model : X ¼ Kt ð3Þ
First order model : log X ¼Kt=2:303 ð4Þ
Higuchi release model : X ¼K tð Þ1=2 ð5Þ
where X is the amount of drug released, K is the release rate
constant, and t is time. To construct the plot for zero order and the
Higuchi model, percent cumulative drug release determined, and
for the ﬁrst order model, log percent drug remaining was determined.
2.2.8. Stability study
The stability study was carried out to determine the effect of the
presence of formulation additives on the stability of drug and also
to determine the physical stability of the prepared formulation
under conditions of storage temperature and relative humidity34.
The optimized HP-SLNs were subjected to stability studies and
the studies were performed in triplicate. The storage conditions
used for stability testing were 472 1C (refrigerator), 2572 1C/
6075% RH, and 4072 1C/7575% in a stability chamber (Hicon
Figure 3 XRD of HP (a), GMS (b) and optimized HP-SLNs (c).
Figure 4 DSC thermograms of haloperidol (a), GMS (b) and
optimized HP-SLNs (c).
Mohd Yasir, Udai Vir Singh Sara458instruments, N. Delhi). The sample was withdrawn after a period
of 0, 1, 3 and 6 months and the effect on particles size, PDI, zeta
potential, entrapment efﬁciency and loading capacity was
determined.
2.2.9. Pharmacokinetics study
A pharmacokinetic study was performed with male albino Wistar
rats (adult/weighing 200–250 g). A protocol for animal studies was
approved by Institutional animal ethical committee and project
number was 03.
The animals were kept under standard laboratory conditions,
temperature of 2273 1C and relative humidity of 30%–70%. The
animals were housed in polypropylene cages, 6 animals per cage
with free access to standard laboratory diet and water ad libitum.
Rats were divided into three groups: group A, positive control for
intravenous (i.v.) drug administration (HP sol.); group B, positive
control for intranasal (i.n.) drug administration (HP sol.); and
group C, intranasal (i.n.) formulation administration (HP-SLNs).
Each group was further divided into 8 subgroups on time basis as
0.167, 0.5, 1, 2, 4, 6, 8 and 24 h, with each group receiving drug at
time 0 and then analyzed at the indicated time. Each subgroup
contained 6 animals. The dose for rats was calculated based on the
body weight and surface area ratio of the rat35. Surface area ratio
calculated for a 200 g rat relevant to a 70 kg human is 56.
The equation is
56¼ dose for human=x ð6Þ
where x is rat dose per 200 g and the dose of HP for human is
10 mg. x¼0.179 mg for 200 g of rat on this basis; the dose
required for rat of 1 kg is 0.893 mg.
Drug solution (positive control), containing 0.179 mg (for 200 g
of rat) of HP (equivalent to 0.89 mg/kg body weight), was injected
through the tail vein (10 mL) of one group of Wistar rats.
Similarly, drug solution and drug formulation (HP-SLNs) contain-
ing 0.179 mg of HP were administered in each nostril in the other
two groups with the help of micropipette (10–100 mL) with
0.1 mm internal diameter at the delivery site. The rats were
anaesthetized prior to nasal administration by pentobarbital sodium
(35–50 mg/kg, i.p.) and held ﬁrmly from the back in a slanted
position during nasal administration.
The rats were killed humanely by an overdose of pentobarbital
sodium at the designated time intervals (0.167, 0.5, 1, 2, 4, 6, 8
and 24 h) and the blood was collected using cardiac puncture in
EDTA-coated Eppendorf tubes. The blood was fractionated at
4000 rpm for 20 min and aliquots of the supernatant separated and
stored at 21 1C until drug analysis was carried out using
HPLC36.
At the same interval of blood collection, the rats were sacriﬁced
to remove the brain. Brain was rinsed twice with normal saline,
made free from adhering tissue/ﬂuid and weighed. Cold normal
saline solution was added (brain weight: normal saline, 1:5) to the
brain and homogenized. The homogenate was centrifuged at
4000 rpm for 20 min with the temperature of 4 1C, and aliquots
of the supernatant were separated and stored at –21 1C until drug
analysis was carried out using HPLC37,38.
Chromatographic separation was achieved with a Cosmosil C18
column (250 mm 4.6 mm, particle size 5 mm). The mobile phase
consisted of 100 mmol/L potassium dihydrogen phosphate–acet-
onitrile–TEA (10:90:0.1, v/v/v) and the pH was adjusted with
o-phosphoric acid to 3.5. The mobile phase was sonicated for
15 min and ﬁltered through a 0.22 μm membrane ﬁlter before use.
The ﬂow rate of the mobile phase was maintained at 2 mL/min andeluents were monitored at 230 nm. Twenty μL of sample was
injected using an HPLC injector. All determinations were per-
formed at ambient temperature for a run time of 5 min.
The extraction of HP from plasma and brain samples was
carried out using the liquid–liquid extraction (LLE) technique.
Plasma sample and homogenized brain tissue (0.5 mL) were mixed
with 100 mL loratidine (100 ng/mL) as an internal standard39,40.
The mixture was shaken with 2 mL isopropyl alcohol for 2 min on
a vortex mixer and then fractionated at 4000 rpm for 10 min until a
clear organic layer was separated. The organic layer was
Figure 5 In vitro drug release from optimized HP-SLNs (a), zero-order release model (b), ﬁrst-order release model (c), and Higuchi release
model (d).
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Dried sample was then reconstituted with 0.3 mL mobile phase
and evaluated by HPLC for the presence of HP.
Plasma concentration–time proﬁles of HP after i.n. and i.v.
delivery were evaluated with pharmacokinetic software (PK
Functions for Microsoft Excel, Pharsight Corporation, Moun-
tain View, CA, USA). Various pharmacokinetic parameters
such as Cmax, Tmax, AUC0–1, AUMC0–1, elimination rate
constant and MRT were calculated. The percent brain targeting
efﬁciency (DTE%) and nose-to-brain direct transport per-
centage (DTP%) were calculated with the help of the following
formulae41.
DTEð%Þ ¼ ½ AUCbrain=AUCblood
 
024; i:n:
=ðAUCbrain=AUCbloodÞ024; i:v:  100 ð7Þ
DTPð%Þ ¼ ½ðAUC024; brain; i:n:–FÞ=AUC0–24; brain; i:n:  100 ð8Þ
whereF¼ (AUC0–24, brain, i.v./AUC0–24, blood, i.v.)AUC0–24, blood, i.n.,
AUC0–24, brain, i.n. is the area under the curve of brain following i.n.
administration, AUC0–24, brain, i.v. is the area under the curve of
brain following i.v. administration, AUC0–24 blood, i.v. is the
area under the curve of blood following i.v. administration, and
AUC0–24 blood, i.n. is the area under the curve of blood following i.n.
administration.2.2.10. Statistical analysis
All data are reported as mean7standard deviation (SD). Differ-
ences between the groups were tested using Student's t-test and
differences among more than two groups were compared using
ANOVA (analysis of variance). A P-value o0.05 was considered
statistically signiﬁcant.3. Results and discussion
3.1. Excipients selection
Excipients used for formulation development should be pharma-
ceutically acceptable, non-irritating, and non-sensitizing in
nature. They should be generally regarded as safe. For the SLNs
development, selection of a suitable lipid and surfactant is
important. Solubility of drug in the lipid is a determinant of
encapsulation efﬁciency. It is expected that high lipid solubility
will result in high encapsulation efﬁciency42.
Solubility studies indicated that in comparison of GMS,
Compritol 888 ATO, precirol ATO 5, stearic acid and palmitic
acid, GMS effectively solubilised the HP (Table 2). The solubilis-
ing potential, coupled with already reported biocompatibility and
acceptability of GMS for nose to brain and parenteral route
delivery favours its selection for the present study23.
The FTIR spectra over the range of 400–4000 cm1 for HP,
GMS and physical mixture of HP and GMS are shown in Fig. 1.
Important peaks at 3120 cm1 appeared the characteristic peak
of OH stretch, at 2951 cm1 aromatic CH group stretch, at
2911 cm1 aliphatic CH2 stretch, at 1676 cm
1 and 1587 cm1
corresponded to CQO carbonyl stretching and a substituted
aromatic ring, respectively, at 1138 cm1 CH deformation of F
substituted aromatic ring, and at 995 cm1 is due to –Cl
substituted aromatic ring43. These characteristic peaks of HP were
also observed in the FTIR spectrum of physical mixture of HP and
GMS without any distinct shifts. This fact veriﬁed that no chemical
interaction between the drug and the polymer had occurred.
On the basis of drug lipid solubility and drug lipid compatibility
study, GMS was selected as the lipid. The criterion for surfactant
selection was its hydrophilic–lipophilic balance (HLB) value that
Table 4 Characteristics of HP-SLNs after a 6-month stability studies at different conditions.
Temp (1C)/RH(%) Time (month) Characteristics parameter
Particle size (nm)a PDI Zeta potential (mV)a Entrapment efﬁciency (%)a Drug loading (%)a
472 0 112.3474.73 0.424 18.671.7 72.5372.64 26.6170.85
1 117.6572.54 0.506 17.671.5 71.5471.20 26.3570.42
3 115.9475.82 0.332 17.371.2 71.2371.94 26.2770.63
6 125.6772.34 0.463 16.172.6 71.9272.45 26.4570.86
2572/6075 0 112.3474.73 0.424 18.671.7 72.5371.64 26.6170.57
1 112.2171.04 0.556 17.371.2 70.6571.24 26.1070.53
3 119.7675.57 0.575 16.671.3 69.7871.98 25.8770.59
6 135.3475.86 0.637 15.172.6 71.8772.34 26.4470.71
4072/7575 0 112.3474.73 0.424 18.671.7 72.5372.64 26.6170.75
1 120.4572.81 0.554 14.271.9 70.3972.85 26.0470.91
3 355.3573.98 0.594 11.672.3 69.5371.27 25.8070.65
6 1345.9374.60 0.642 8.3473.9 70.3672.54 26.0370.89
PS, Particle size; PDI, polydispersity index.
aData are expressed as mean7SD, n¼3; Po0.05 (The measurements obtained at each time point (1, 3 and 6 months) at speciﬁc storage condition
were compared with measurements obtained at zero month at that storage condition. Comparison of different parameters was also made between
different temperatures.)
Table 5 Pharmacokinetic parameters of HP after HP-SLNs i.n., HP sol. i.n. and HP sol. i.v. administration to rats in brain and plasma.
Parameter (unit) SLNs i.n. Drug solution i.n. Drug solution i.v.
Brain Plasma Brain Plasma Brain Plasma
Cmax (ng/mL) 329.17720.89 393.5724.63 90.1376.28 306.96713.47 76.9577.62 2190760.67
Tmax (h) 2 4 2 1 1 0.167
AUC0–24 h (ng  h/mL) 2172.33760.41 2433.05718.54 623.1678.51 1460.71715.67 433.65715.46 11,464.597150.45
AUC0–1 (ng  h/mL) 2389.17778.82 2612.31740.67 683.15730.17 1681.82732.83 500.82712.78 12,017.57180.87
AUMC0–24 h (ng  h2/mL) 12,172.67756.59 13,725.217135.43 2881.23727.08 8696.867124.78 2881.31730.76 57,642.097580.45
AUMC0–1 (ng  h2/mL) 15,665.20725.59 19,864.677256.43 7079.16735.53 14,650.317145.75 5199.467120.67 70,374.147960.87
Ke (h
1) 0.07970.0065 0.09770.003 0.07770.005 0.1170.003 0.09570.003 0.1570.007
MRT (h) 12.6070.99 7.6070.32 9.1770.45 8.970.57 10.3870.65 5.9270.57
All data are expressed as mean7SD, n¼6; Po0.05 (Pharmacokinetics parameters after various route of administration were compared with each
other).
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acceptable concentration. Tween 80 with HLB of 15 was selected
as the surfactant.
3.2. Evaluation of HP-SLNs
3.2.1. Particle size, zeta potential and morphology study
The concentration of the surfactant (Tween 80) was optimized in
order to obtain a smaller size of SLNs with maximum percent drug
entrapment. The concentration of the surfactant was optimized to
1.625% w/v.
The mean particle size of different batches of SLNs ranges from
115.172.78 to 156.7773.95 nm. The particle size of optimized
batch (OPH) batch was appreciably lower (115.172.78 nm)
compared to other batches. This is due to the addition of surfactant
to solid lipid nanoparticles that causes the interfacial ﬁlm to
condense and stabilize44. All batches had particles in the nano
range which is well evident from the values of PDI. PDI isessentially the ratio of standard deviation to the mean particle size.
The value of PDI was acceptable for all batches (Table 3).
On increasing the stirring time and stirring speed from 2 to
2.5 h and from 2000 to 3000 rpm (data is not shown), a decrease in
the particle size was observed for all the batches; an increase in the
percent of drug entrapment was also observed. On a further
increase a marginal increase in particle size was observed. Hence,
stirring time and stirring speed were optimized to 2.5 h and
3000 rpm, respectively. Similar ﬁndings have also been reported
by Singh et al.23.
Percent drug loading and percent drug entrapment efﬁciency of
the optimized batches were found to be 26.3570.56 and
71.5670.1.56, respectively (Table 3). For the optimized batch,
a dense roughly spherical pattern was observed by transmission
electron microscopy (Fig. 2). The surface carried negative charges
with a zeta potential of 16.7 mV when the drug-to-lipid ratio,
surfactant concentration, stirring time, and stirring speed were 1:2,
1.625% (w/v), 2.5 h and 3000 rpm, respectively.
Figure 6 Drug concentration versus time proﬁle of HP in blood and brain after administration of HP-SLNs i.n. (a), HP sol. i.n. (b) and HP sol. i.v. (c).
Table 6 DTE (%) and DTP (%) of optimized HP-SLNs i.n.
and HP sol. i.n.
Formulation and route of
administration
DTE (%) DTP (%)
HP-SLNs 2362.43 95.77
HP sol. 1128.61 91.14
Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation 4613.2.2. X-ray diffractometric analysis
The X-ray defraction (XRD) pattern of HP showed sharp peaks at
2θ-scattered angles at 15.51 and 20.51, indicating the highly
crystalline nature of the drug. The XRD pattern of GMS showed
a peak at about 201, indicating the crystalline nature of the lipid.
The principal peak of HP is absent in SLN XRD spectra.
Furthermore, the principal peak of lipid did not shift but had a
reduced intensity as compared to free lipid. This may be attributed
to the incorporation of HP between the parts of the crystal lattice
of the lipid, leading to a change in the crystallinity of the HP-SLNs
(Fig. 3).3.2.3. Differential scanning calorimetry
The DSC thermogram of HP showed a melting peak of 151.895 1C
while GMS and optimized HP-SLNs showed at 60.376 1C and
55.856 1C, respectively (Fig. 4). The thermogram of SLNs did not
show the melting peak of crystalline haloperidol around
151.895 1C, indicating that the drug was completely solubilized
inside the lipid matrix and was in the amorphous form. The
melting peak of GMS in SLNs was decreased by 4.52 1C,
suggesting that GMS in SLNs might be in crystalline form. The
decrease in the melting point of SLNs loaded with haloperidol was
due to their small particles size that lead to high surface energy,
creating an energetically suboptimal state as described by the
Thomson equation45.3.2.4. In vitro release and release kinetics studies
For the optimized batch, release from 10.9872.96% to
94.1674.78% was obtained as the drug slowly diffused through
the lipid core (Fig. 5a). The drug release data was ﬁtted into zero-
order, ﬁrst-order and Higuchi kinetics models22. For the optimized
batch, the highest value of the correlation coefﬁcient (R2¼0.9941)
was observed for Higuchi's model, followed by the ﬁrst-order(R2¼0.9894) and zero order (R2¼0.8842) models, as shown in
Fig. 5.
3.2.5. Stability studies
No signiﬁcant change was observed in particle size when they
were stored at 472 1C (refrigerator) and 2572 1C/6075% RH,
but the size of particles increased when the they were stored at
4072 1C/7575% RH due to aggregation (Po0.05, Table 4).
Zeta potential plays an important role in physical stability.
There was no signiﬁcant change between 472 1C (refrigerator)
and 2572 1C/6075% RH, but zeta potential dropped at
4072 1C/7575% RH (Po0.05). This might be due to dissolution
of the coating of lipid which leads to aggregation of particles.
3.2.6. Pharmacokinetics studies
The HP concentrations in brain following the i.n. administration of
HP-SLNs were found to be signiﬁcantly higher at all the time
points as compared to both HP sol. i.n. and HP sol. i.v. (Po0.05).
The haloperidol concentration in plasma following the i.n. of HP-
SLNs was found to be signiﬁcantly lower at all the time points
compared to HP sol. i.v. administration (Po0.05, Table 5). Fig. 6
shows the drug concentration versus time proﬁle of HP in blood
and brain after (a)HP- SLNs i.n., (b) HP sol. i.n., and (c) HP sol. i.v.
Various pharmacokinetic parameters of HP were calculated by using
PK Functions for Microsoft Excel (Pharsight Corporation, Mountain
View, CA, US) as shown in Table 5. The lower value of Tmax for
brain (2 h) as compared to blood (4 h) may be attributed to the
preferential nose to brain transport following i.n. administration.
The values of Cmax and AUC of brain for HP sol. i.n., HP sol. i.v.
and HP- SLNs i.n. were compared, the value of Cmax
(329.17720.89 ng/mL) and AUC0–1 (2389.17778.82 ng  h/mL)
of HP-SLNs were found to be signiﬁcantly higher than HP sol. (i.n.
and i.v.) because of the direct transport of drug through olfactory
route by bypassing the BBB.
The value of AUC0–1 in brain for HP-SLNs i.n. was found to
be nearly 4.77 times higher than that of HP sol. i.v., whereas 3.49
times higher than HP sol. i.n. This result reveals that drug uptake
into the brain from the nasal mucosa mainly occurs via two
different pathways. One is the systemic pathway by which some of
the drug is absorbed into the systemic circulation and subsequently
reaches the brain by crossing the BBB. The other is the
olfactory pathway by which the drug partly travels from the nasal
cavity to CSF and/or brain tissue46,47. The DTE% and DTP%
represent the percentage of drug directly transported to the brain
via the olfactory pathway. The higher DTE (2362.43%) and DTP
(95.77%) were found with HP- SLNs (Table 6). Higher DTE (%)
Mohd Yasir, Udai Vir Singh Sara462and DTP (%) suggest that HP-SLNs have better brain targeting
efﬁciency. Similar types of results have also been reported by
Zhang et al.48.4. Conclusions
The present research work proposed a lipid nanoparticulate drug
delivery system (SLNs) for intranasal delivery of HP. SLNs were
prepared by the modiﬁed emulsiﬁcation–diffusion technique and
evaluated for particle size, particle size distribution (PDI),
zeta potential, entrapment efﬁciency, in vitro release and stability
studies. All measurements were found to be in an acceptable
range. In vitro drug release was found to be 94.1474.78%
over 24 h, indicating a controlled and sustained release proﬁle of
HP-SLNs. Pharmacokinetics studies were performed on Wistar
rats, in which the DTE (%) and DTP (%) are more indicative of
direct nose to brain transport bypassing the BBB thereby
representing the superiority of HP-SLNs over HP sol. i.n. and
i.v. It was concluded that HP-SLNs could be an effective drug
delivery system for the treatment of psychiatric conditions like
schizophrenia via nose to brain route. However, clinical data is still
needed to evaluate the risk/beneﬁt ratio.Acknowledgments
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